Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
Type:
Application
Filed:
May 15, 2009
Publication date:
December 31, 2009
Applicant:
Oxxon Therapeutics Ltd.
Inventors:
Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
Abstract: The present invention is directed to a method of inducing an immune response against a hepatitis B antigen (e.g., an antigen from a hepatitis B virus) in a mammal, which comprises administering to the mammal a priming composition (e.g., a DNA plasmid), comprising a source of one or more epitopes of the hepatitis B target antigen; and a boosting composition, comprising a source of one or more eptiopes of the hepatitis B target antigen (e.g., a non-replication or replication-impaired poxvirus such as MVA), wherein at least one epitope of the boosting composition is identical to an epitope of the priming composition. The present invention also is directed to a method of inducing an immune response against a hepatitis B antigen (e.g., an antigen from a hepatitis B virus) in a mammal, which comprises administering to the mammal a priming composition (e.g., a DNA plasmid), comprising a source of one or more epitopes of the hepatitis B target antigen.
Type:
Application
Filed:
November 20, 2007
Publication date:
October 30, 2008
Applicant:
Oxxon Therapeutics Ltd.
Inventors:
Joerg Schneider, James Chorlton, Gill Pearce, Nicola Jones, Dean Brown
Abstract: The invention relates to a recombinant polypeptide comprising amino acid sequence derived from at least one of an HIV gag gene product; an HIV pol gene product; or an HIV nef gene product, said sequence being mutated with respect to the natural sequence of said gene product, and said sequence maintaining each of the naturally occurring CD8+ T cell epitopes of said gene product as defined in p17 and p24 (gag), amino acids 1-440 of RT (pol) and nef shown in Example 8. Furthermore the invention relates to nucleic acids encoding same, and viral vectors encoding same, and to their use in medicine and in immunisation and vaccination.
Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
Type:
Application
Filed:
April 28, 2004
Publication date:
October 7, 2004
Applicant:
Oxxon Therapeutics Ltd.
Inventors:
Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
Type:
Application
Filed:
April 28, 2004
Publication date:
September 30, 2004
Applicant:
Oxxon Therapeutics Ltd.
Inventors:
Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
Type:
Application
Filed:
April 28, 2004
Publication date:
September 9, 2004
Applicant:
Oxxon Therapeutics Ltd.
Inventors:
Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard